Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarction

Fig. 3

FNDC5/irisin reduced the increased apoptosis of BM-MSCs with hypoxia for 48 h. a Results of the flow cytometry analyses in BM-MSCs under normoxia, hypoxia for 48 h, H/SD + FNDC5-MSCs, and HS/D + irisin (scale bars, 20 μm). b, c Representative quantification of the apoptotic BM-MSCs under different treatments. d Histogram illustrating the caspase-3 enzymatic activity in BM-MSCs after various treatments. e Representative in vitro BLI results of MSCsFluc+GFP+ with normoxia, hypoxia for 48 h, H/SD + FNDC5-MSCs, and HS/D + irisin. f Representative quantification of BLI assays in different groups. g MTT assay demonstrated the effects of FNDC5-OV/irisin on the viability of MSCsFluc+GFP+. Data are expressed as the means ± SEM; n = 5; *p < 0.05

Back to article page